See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Muu" projekt MARBS13184R
MARBS13184R "Hübriidsete fluorestseeruvate proovide väljatöötamine vähidiagnostikaks (1.11.2013−31.10.2016)", Tambet Teesalu, Tartu Ülikool, Arstiteaduskond, Bio- ja siirdemeditsiini instituut, Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut, Tartu Ülikool, Arstiteaduskond, Biomeditsiini instituut.
MARBS13184R
Hübriidsete fluorestseeruvate proovide väljatöötamine vähidiagnostikaks
Binding-activated fluorescent DNA/peptide chimeric probes for cancer imaging
CHIMERA
1.11.2013
31.10.2016
Teadus- ja arendusprojekt
Muu
ValdkondAlamvaldkondCERCS erialaFrascati Manual’i erialaProtsent
3. Terviseuuringud3.1. BiomeditsiinB726 Kliiniline bioloogia 3.1. Biomeditsiin (anatoomia, tsütoloogia, füsioloogia, geneetika, farmaatsia, farmakoloogia, kliiniline keemia, kliiniline mikrobioloogia, patoloogia)100,0
AsutusRollPeriood
Tartu Ülikool, Arstiteaduskond, Bio- ja siirdemeditsiini instituutpartner01.01.2014−31.12.2015
Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituutpartner01.01.2016−31.10.2016
Tartu Ülikool, Arstiteaduskond, Biomeditsiini instituutpartner01.11.2013−31.12.2013
AsutusRiikTüüp
Euroopa Komisjon
PerioodSumma
01.11.2013−31.10.201654 600,00 EUR
54 600,00 EUR
7. raamprogramm

The overriding goal of this project is to mimic Nature in the design of novel nucleic acid/peptide chimera based nanodevices that can enable cancer imaging. We will design, engineer and optimize highly specific biomolecular nanodevices that undergo binding-induced conformational changes upon target binding and, in doing so, signal the presence of the cancer marker. This scientific goal of great relevance for the clinical implications will be achieved bringing together an international and interdisciplinary group of research teams and building a collaborative environment for research, innovation and technology transfer. This program will allow the exchange of knowledge and expertise through visiting training periods for participating early-stage and experienced researchers. The training will involve each single aspect of probe development and cancer imaging. The research teams involved in this project encompass the requisite expertise and each of them has a particular focus on a single step of optical probe development and testing on cancer cells. This program will help the integration and collaboration among the research teams and the establishment of a long-term collaboration between Europe and key Third Countries.
The overriding goal of this project is to mimic Nature in the design of novel nucleic acid/peptide chimera based nanodevices that can enable cancer imaging. We will design, engineer and optimize highly specific biomolecular nanodevices that undergo binding-induced conformational changes upon target binding and, in doing so, signal the presence of the cancer marker. This scientific goal of great relevance for the clinical implications will be achieved bringing together an international and interdisciplinary group of research teams and building a collaborative environment for research, innovation and technology transfer. This program will allow the exchange of knowledge and expertise through visiting training periods for participating early-stage and experienced researchers. The training will involve each single aspect of probe development and cancer imaging. The research teams involved in this project encompass the requisite expertise and each of them has a particular focus on a single step of optical probe development and testing on cancer cells. This program will help the integration and collaboration among the research teams and the establishment of a long-term collaboration between Europe and key Third Countries.
TegevusProtsent
Alusuuring100,0